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Predictive Value of the
Uterotrophic Assay for
Genistein Carcinogenicity in
the Neonatal Mouse: Relevance
to Infants Consuming Soy-
Based Formula
Markey et al. (1) recently questioned the sen-
sitivity to estrogens of the rodent uterotrophic
assay. However, an example of the biological
validity of this assay was recently provided by
studies on diethylstilbestrol (DES) and genis-
tein by Newbold et al. (2). These investigators
used the neonatal mouse uterotrophic assay
to define estrogen-equivalent subcutaneous
(sc) injection doses of these two chemicals: 1
µg/kg/day DES and 50 mg/kg/day genistein
(a difference of 50,000-fold; Table 1). This
estrogen-equivalent factor is identical to obser-
vations in similarly conducted weanling
mouse uterotrophic assays of DES and genis-
tein (Table 1) (3). Newbold et al. (2) also used
the same dose levels to evaluate neonatal car-
cinogenicity of DES and genistein in the
mouse uterus; they observed similar incidences
of uterine adenocarcinomas with both chemi-
cals in 18-month-old mice (Table 1). This
confluence of findings in the neonatal and
weanling mouse, and the similar carcinogenic
potency of the two chemicals when evaluated
at uterotrophic-equivalent dose levels, is
encouraging for the utility of the rodent
uterotrophic assay for predicting adverse
effects in rodents. In particular, the fact that
there is insufficient genistein in soy-based
infant formula to trigger a uterotrophic
response in rodents drinking the formula ad
libitum indicates the probable absence of a
carcinogenic hazard under normal conditions
of use (4). It is of interest that the estrogen-
equivalent dose levels of these two chemicals
in estrogen receptor binding assays are sepa-
rated by a factor of only 9,000 (5). The
expansion to the 50,000 factor seen in the
mouse assays is probably associated with dis-
parities in target tissue dose due to differences
in serum protein binding and excretion of the
two chemicals in vitro and in vivo, differences
that would need to be evaluated separately for
humans.
Newbold et al. (2) suggested that the
neonatal carcinogenicity of genistein should
trigger a close examination of the potential
hazard posed to infants by the consumption
of soy-based infant formula, because genis-
tein is the major isoflavone phytoestrogen
formed from ingestion of soy products. The
need for such a review was based on the
assumption that 50 mg/kg/day genistein by
sc injection, as used in the neonatal carcino-
genicity bioassay, was representative of the
levels of exposure to genistein experienced
by infants fed soy formula (2). Given the
potential societal interest in these new data
(2), we suggest that the following facts
should form a part of any review of the use
of soy infant formula. First, genistein shows
remarkable differences in route of adminis-
tration in the uterotrophic assay, with the sc
route being substantially more sensitive
than the oral route (3). Thus, the use of the
sc route by Newbold et al. (2) will
inevitably have exaggerated the hazard
posed to infants drinking soy formula.
Second, the work of Setchell et al. (6), quot-
ed by Newbold et al. (2) to support the rele-
vance to infants of their dose of 50
mg/kg/day genistein, actually estimated that
infants drinking soy formula are exposed to
6–11 mg/kg/day total isoflavones, a figure
slightly higher than the 4.5 mg/kg/day esti-
mated by the U.K. Food Standards Agency
(7). In fact, oral administrations of genistein
in this dose range (6,7) are inactive in the
uterotrophic assay (3,4,8). Third, the major
isoflavone in soy formula is not genistein,
but rather its glycone conjugate, genistin
(6). This conjugate is transformed into the
estrogen genistein in the gut, a transforma-
tion attenuated in infants (6). Thus, it is
tenuous to relate experimental data derived
from the sc injection of genistein to the haz-
ard posed to infants by drinking infant for-
mula containing the glycone genistin.
Fourth, the mouse chow used by Newbold
et al. (2) (NIH-31) contained 46 µg genis-
tein/g diet, which is similar to the 42 µg
genistein/g in the RM1 diet (9) used by
Ashby (3). Consequently, the control and
test pups used in the carcinogenicity bioas-
say of genistein were potentially exposed to
low levels of genistein in utero via the milk,
and in their lifetime by the diet (a mouse
weighing 25 g eating 4 g of diet a day would
be exposed to ~7 mg/kg/day genistein,
together with other isoflavones and their
conjugates). The zero incidence of uterine
adenocarcinomas in the control animals
used by Newbold et al. (2) therefore sug-
gests the existence of a threshold dose for
the carcinogenicity of genistein, as observed
in the uterotrophic assay (3). A final com-
plication to the proposed safety review on
infant formula is that uterotrophic activity
and advanced sexual development is
observed in rodents exposed to commercial
infant formula via their drinking bottles (4).
These effects were unrelated to the con-
stituent phytoestrogens but were associated
with centrally mediated nutritional influ-
ences leading to advanced puberty (4,9). 
In conclusion, although the neonatal
carcinogenicity of genistein is of significant
scientific interest, the test protocol employed
in the generation of those data render them
of little value for purposes of infant risk
assessment. In particular, the exposures to
genistein experienced by the mouse neonates
may have been several orders of magnitude
higher than those experienced by infants
drinking soy-based formula.
John Ashby
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Table 1. Confluence of the neonatal and weanling mouse uterotrophic assay data and the neonatal mouse
uterine carcinogenicity data for DES and genistein. 
Period of dosing; assay end point DES (1 µg/kg/day) Genistein (50 mg/kg/day)
(reference) [~0.002 µg/neonate] [~100 µg/neonate]
PND 1–5; uterotrophic assay at PND 5 (2) 190% uterine weight gain 202% uterine weight gain
PND 20–23; uterotrophic assay at PND 24 (3) 200% uterine weight gain 240% uterine weight gain
PND 1–5; incidence of uterine adenoma at 18 m (2) 31% 35%
All of the data compared involved sc injection of the test agents at the postnatal days (PND) shown. There were no uterine
adenocarcinomas in the control mice (2).The Mouse Uterotrophic
Assay: Other End Points
In their EHP article titled “The Mouse
Uterotrophic Assay: A Reevaluation of Its
Validity,” Markey et al. (1) argue against
using the uterotrophic assay as an end point
for determining estrogenicity of synthetic
chemicals. They conclude (1), 
The uterotrophic assay is of limited value in
determining the estrogenicity of a suspected
environmental estrogen because changes at the
cellular level were observed at significantly lower
doses than those at which a change in wet
weight occurred.
In agreement with their findings, we have
similar data which show that many cellu-
lar and biochemical end points in the
uterus, such as epithelial cell height, cell
number, gland number, and lactoferrin
induction, are often more sensitive end
points than wet weight increase. We have
reported this information at international
meetings and have shared our findings
with the U.S. Environmental Protection
Agency’s Endocrine Disruptor Screening
and Testing Advisory Committee. We have
also compared the sensitivity of different
end points for 10 compounds over a large
dose range for each chemical (2). However,
we disagree with the conclusion of Markey
et al. (1) that the uterotrophic assay has
limited value. Our increasing knowledge
about the various actions of estrogens now
makes it feasible to expand the uterotrophic
assay to include information about different
pathways and end points. Thus, we suggest
that the uterotrophic assay be expanded to
encompass additional measures to the stan-
dard wet weight data to increase its sensitiv-
ity. The objective of studying these end
points when the uterotrophic assay is nega-
tive is to eliminate false negatives. Further,
mechanistic information can be gained by
developing a “blueprint” of responses for
various estrogenic compounds. The mouse
uterotrophic assay is valid: a reevaluation of
the assay should assure that the assay is
optimized so that meaningful and informa-
tive end points are included that cover a
range of effects induced by the chemicals
under study.
Two other points are worthy of men-
tion. Numerous studies appearing in the
literature report data from the uterotrophic
bioassay as wet weight increase, when in
fact they are reporting “blotted” uterine
weight. The true wet weight of the uterus
includes uterine tissue plus luminal fluid.
Recording only “blotted” weight overlooks
the significant role estrogens play in uterine
water imbibition, an early marker of estro-
gen action. This is an important end point
that again makes the assay more sensitive. 
Another important point is that prolifer-
ating cell nuclear antigen (PCNA), or any
other marker of uterine cell proliferation,
may give erroneous results if measured after 3
days of continuous treatment with an estro-
gen, as described by Markey et al. (1).
Estrogens are known to increase mitosis, but
they also act to inhibit mitosis if the estrogen
dose is too high or if it is sustained (Table 1).
This may explain why the authors found no
significant difference in the expression of
PCNA in the luminal epithelium between
treatment groups (control, estradiol, and
bisphenol A), although other studies have
shown increases in PCNA expression follow-
ing treatment with these same compounds
(3). Using time-course experiments in the
immature mouse, we have determined that
excellent PCNA labeling occurs 18 hr after
an initial dose of estradiol or diethylstilbestrol
(DES) (2). The time for maximum stimula-
tion of mitosis varies with the pharmacoki-
netics of the compound being tested (2), but
most chemicals, including known estrogens
that we have tested thus far, showed slight or
no increase in mitosis after 3 days of treat-
ment. In fact, mitosis is inhibited by 3 days
of treatment with DES (Table 1).
In summary, we agree with Markey et
al. (1) that the current uterotrophic bioassay
(consisting of only wet weight) is not sensi-
tive, and we encourage a reevaluation of the
assay in the framework of the information
presented.
Retha R. Newbold
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Health Sciences
Research Triangle Park, North Carolina
E-mail: newbold1@niehs.nih.gov
REFERENCES AND NOTES
1. Markey CM, Michaelson CL, Veson EC, Sonnenschein C,
Soto AM. The mouse uterotrophic assay: a reevaluation
of its validity in assessing the estrogenicity of bisphenol
A. Environ Health Perspect 109:55–60 (2001)
2. Newbold RR, Jefferson WN, Padilla-Banks E, Walker VR,
Pena D. Cell response endpoints enhance the sensitivity
of the immature mouse uterotrophic assay. Reprod
Toxicol 15:245–252 (2001).
3. Klotz DM, Hewitt SC, Korach KS, DiAugustine RP.
Activation of a uterine insulin-like growth factor I signal-
ing pathway by clinical and environmental estrogens:
requirements of estrogen receptor α. Endocrinology
141:3430–3439 (2000).
4. Shelby MD, Newbold RR, Tully DB, Chae K, Davis VL.
Assessing environmental chemicals for estrogenicity
using a combination of in vitro and in vivo assays.
Environ Health Perspect 104:1296–1300 (1996).
5. Foley J, Ton T, Maronpot R, Butterworth B, Goldsworthy
TL. Comparison of proliferating cell nuclear antigen to triti-
ated thymidine as a marker of proliferating hepatocytes in
rats. Environ Health Perspect 101(suppl 5):199–205 (1993).
The Rodent Uterotrophic
Assay: Response to Ashby
and Newbold et al. 
The comments submitted by Ashby et al.
and Newbold et al. reflect disagreement
with our statement that the classical mouse
uterotrophic assay is of limited use in
assessing the estrogenicity of chemicals. We
restate here that the uterotrophic assay is a
relatively insensitive test for determining
whether a chemical is estrogenic, for estab-
lishing no-observed-effect levels (NOELs),
and ultimately for predicting the level of
exposure at which adverse effects may
occur. Ashby and colleagues cite a recent
publication by Newbold et al. (1) as “an
example of the biological validity of this
[uterotrophic] assay.” The study to which
Ashby et al. refer shows that exposure of
neonatal mice to daily injections from post-
natal days 1–5 of either genistein (50
mg/kg/day) or DES (1 µg/kg/day) induces
a uterotrophic response by the end of day 5
and uterine adenocarcinoma by 18 months
of age. Ashby et al. interpret “this conflu-
ence of findings” as being “encouraging for
the utility of the rodent uterotrophic assay
for predicting adverse effects in rodents.” 
First, the study of Newbold et al. (1)
does not conform to the classic use of the
uterotrophic assay. This assay is character-
ized by a 3-day exposure of an adult ovariec-
tomized or juvenile (prepubertal) rodent to
a chemical, or in the case of the develop-
mental uterotrophic assay, a 12-day expo-
sure of a rodent from postnatal day (PND)
10 to PND 22 (2). Newbold et al. (3) cited
Bern’s study (4), which shows that the peri-
natal mouse is far more sensitive to the
effects of estrogen exposure than the prepu-
bertal or adult mouse, a widely held tenet in
the field of endocrine disruption. 
Second, by using a single dose of genis-
tein and DES, the study of Newbold et al.
(1) was not aimed at determining the mini-
mal exposure that would cause an effect for
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Table 1. PCNA-labeled uterine epithelial cells
after treatment with DES or estradiol.
Percent 
Treatment PCNA-labeled cells
Control 5.92 ± 0.79
DES 1× 31.81 ± 3.78*
Estradiol 1× 46.67 ± 3.68*
DES 3× 1.23 ± 1.23
Estradiol 3× 9.60 ± 0.84
Immature outbred CD-1 mice were administered 10 µg/kg
DES or 500 µg/kg estradiol dissolved in corn oil by sc
injection for 1 day or 3 days and sacrificed the morning
following the last injection (2). These doses of DES and
estradiol have been previously determined to cause max-
imum uterine wet weight increase (4). Uterine tissues
were collected and PCNA was determined by previously
described methods (2,5).
*p<0.05; statistically significant difference from control
by ANOVA.A 570 VOLUME 109 | NUMBER 12 | December 2001 • Environmental Health Perspectives
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the end points of uterine wet weight and
uterine adenocarcinoma at these ages. To
emphasize this point, previous work from
Newbold’s group has demonstrated that
exposure of neonatal mice to a 10-fold
lower dose of genistein (5 mg/kg) resulted
in the development of multi-oocyte follicles
by 2 months of age (5), an effect that is
likely to compromise fertility. Yet, a 3-day
exposure of prepubertal mice (days 17–19)
to < 50 mg/kg genistein was insufficient to
induce a uterotrophic response (6). Thus,
for the parameter of multi-oocyte follicles,
the uterotrophic assay is not predictive. 
Third, induction of adenocarcinoma is
the most extreme of biological end points
to consider, particularly in a field that is
attempting to tease out the subtleties of
biological perturbations due to chemical
exposure in populations characterized by
variation. Again, to emphasize this point,
Newbold (7) demonstrated that exposure
of CD-1 mice to 100 µg/kg DES on gesta-
tional days 9–16 induced uterine adenocar-
cinoma; yet a dose of DES that was
10,000-fold lower (0.01 µg/kg) resulted in
reduced reproductive capacity. By using the
uterotrophic assay to establish the estro-
genicity of bisphenol A (BPA), it can be
concluded that exposure to a dose < 100
mg/kg/day is not detrimental to CD-1
mice. However, exposure of the same strain
of mice during gestational days 9–20 to
doses of BPA 4,000 times lower (25
µg/kg/day) induced profound proliferative
changes in the lobuloalveolar network of
the adult mammary gland (8). We also
observed the persistence of epithelial struc-
tures that have been shown to be sites of
neoplasia in rodents and humans, and an
alteration in DNA synthesis between the
epithelium and stroma, which is the sub-
stratum of neoplasia in this tissue (8). 
Ashby’s statement that there is “insuffi-
cient genistein in soy-based infant formula
to trigger a uterotrophic response in rodents”
which “indicates the probable absence of a
carcinogenic hazard” leads him to conclude
that the dose of genistein found in infant
formula is not of biological concern. This
rationalization clearly demonstrates the dan-
gerous misuse of the uterotrophic assay that
we pointed out in our paper in
Environmental Health Perspectives (9). 
Newbold et al. support our findings that
“many cellular and biochemical end points in
the uterus … are often more sensitive end
points than wet weight increase,” yet they dis-
agree with our purported conclusion that the
uterotrophic assay has limited value. We con-
cluded that “the uterotrophic assay is of limit-
ed value in assessing the estrogenicity of a sus-
pected environmental estrogen” (9), and we
maintain this position on the basis of our
work and that of others. Research by
Newbold and colleagues clearly demonstrates
this phenomenon (3). This group’s study
showed that exposure of prepubertal mice
(days 17–19) to a variety of chemicals
induced a uterotrophic response in all cases
except with endosulfan and kepone. In spite
of an observed increase in the number of uter-
ine glands and PCNA labeling, these two
chemicals were not able to induce a
uterotrophic effect at any dose, even at those
doses that were toxic to the animal (endosul-
fan). Although this work provides a seminal
contribution to the field of endocrine disrup-
tion, it cannot claim to have “compared the
sensitivity of different end points, for 10 com-
pounds, over a large dose range for each
chemical.” Newbold et al. (3) described a
dose–response curve for 10 chemicals, using
the uterotrophic assay as the end point. Then,
they tested the change in various cellular and
biochemical end points at the dose that
induced the maximal uterotrophic response. 
We agree with the statement of Newbold
et al. that the mouse uterotrophic assay
should be “optimized so that meaningful
and informative end points are included that
cover a range of effects induced by the
chemical under study.” However, we pro-
pose that this modified assay be renamed so
as not to be confused with the classical
mouse uterotrophic assay, which is simply a
measure of the increase in uterine wet weight
after exposure to a chemical. In redefining
the assay, we should consider the statement
by Roy Hertz (10) who suggested that 
the sine qua non of estrogenic activity remains
the mitotic stimulation of the tissues of the
female genital tract. A substance which can
directly elicit this response is an estrogen; one
that cannot do this is not an estrogen.
In regard to the issue of measuring uter-
ine wet weight versus “blotted” weight that
was raised by Newbold et al. in their letter,
we believe that a universally accepted tech-
nique should be used by all researchers to
accommodate a valid comparison of data. In
our study, we chose to define uterine weight
as “blotted” because we believe that it is
closer to the ideal of Hertz (10), as outlined
above, which asserts that mitotic activity is
the best index of an estrogenic effect. 
In conclusion, we maintain our original
position that the uterotrophic assay is not
sufficiently sensitive to be used as a tool to
determine whether or not a chemical is
estrogenic or to establish NOELs. In the
absence of other more sensitive end points,
relying on the uterotrophic assay alone to
make statements that exposure to certain
estrogenic chemicals is not of biological con-
cern, as appears to be the modus operandi of
some researchers in the field, is hazardous to
the health of all species. 
Caroline M. Markey
Cheryl L. Michaelson
Electra C. Veson
Carlos Sonnenschein
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Are All Cigarettes Equal?
Ezzati and Kamen (1) correctly add an
increment to the estimated personal expo-
sure of smokers in their Kenyan cohort to
account for the mass of particulate matter
(PM) that is inhaled directly from the
mainstream smoke (2). However, the
authors added only 1,000 µg/m3 to the
smoker’s personal total PM exposure.
Kenyan smokers can choose between smok-
ing Kiraiku (home processed, hand-rolled
tobacco) and commercial filtered and non-
filtered cigarettes (3). I expect that smoking
of Kiraiku and nonfiltered commercial cig-
arettes may well deliver much more than 17
mg of tar per cigarette (4). Thus, if the
authors’ cigarette-smoking subjects actually
smoked even one such cigarette per day,
they would have an increment to their per-
sonal exposure that would be much larger
than 1 mg/m3. Environmental Health Perspectives • VOLUME 109 | NUMBER 12 | December 2001 A 571
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Are All Cigarettes Equal?:
Response
Mage raises the issue of exposure to particu-
late matter from smoking in our study of
indoor smoke and acute respiratory infec-
tions in Kenya (1), but the points he raises,
although correct, are not applicable in this
context. In our study area, smoking was
very uncommon. Only a small subset of the
group smoked cigarettes (a total of 13 in
our study group). Those who did smoke did
so very infrequently, often not even on a
daily basis, and they often shared their ciga-
rettes because of the cost of cigarettes and
because the most common habit in the area
is chewing the leaves of the Mirraa plant.
Although there are different types of ciga-
rettes and tobacco available in Kenya, we
only encountered commercially manufac-
tured cigarettes in our study. 
We added 1 mg/m3 to the personal total
PM exposure for smokers. We obtained this
value by assuming a PM10 concentration of
400 mg/m3 and approximately 4 min of
active inhalation. In addition to being a
source of particulate matter, smoking was
considered as an independent factor in
Tables 4 and 5 of our paper (1) to estimate
its independent contribution to disease, a
more informative source of information. By
considering cigarette smoke as a source of
PM, we acknowledged this parallel between
the two pollutants (while emphasizing the
differences in their other properties such as
carcinogenesis). 
With the uncertainties in assessment of
exposure to pollution from cooking and
using wide exposure categories, the small
number of smokers, and multiple analyses
approaches, our findings are not sensitive to
the exact level of exposure to PM from
smoking. 
Majid Ezzati
Resources for the Future 
Washington, DC
E-mail: ezzati@rff.org
Daniel M. Kammen
University of California
Berkeley, California
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Re: Risk Assessment of
Internal Cancers from Arsenic
in Drinking Water
Arsenic in drinking water was the first envi-
ronmental health problem to be recognized.
It has been regulated for 100 years, first by
the British Royal Commission on Arsenic
Poisoning of 1903 (1), then by individual
states in the United States, by the U.S.
Department of Health in 1942, and since
1970, by the U.S. Environmental Protection
Agency (U.S. EPA) (2). The scientific basis
of all arsenic standards, including the present
50 µg/L drinking water standard, is the toxic
threshold concentration of around 250 µg/L
(1). Arsenic-related skin cancer has that same
threshold (2). Morales et al. (3) should have
acknowledged the contradiction of their
bladder cancer interpretation with the much
stronger skin cancer evidence.
The U.S. EPA decided to regulate
chemicals with a procedure called “Risk
Assessment” that extrapolates risk below the
threshold to a point of 1/10–6 risk as the
regulatory target, or roughly 10,000 times
below the threshold concentration. The 50 µg/L
standard already is as strict as is feasible. The
U.S. EPA did not apply risk assessment to
arsenic for 30 years and continued to use
the 50 µg/L standard. Now, in a controver-
sial proposal, the U.S. EPA proposes to
lower the standard 5-fold, using as official
justification (4) the risk assessment by
Morales et al. (3). The authors (3) state that 
… our analysis suggests that the current standard
of 50 µg/L is associated with a substantial increased
risk of cancer and is not sufficiently protective of
human health.
The evidence presented by Morales et
al. (3) in Table 5 of their paper can be inter-
preted as showing no increased risk in the
0–400 µg/L concentration range. Numbers
of cases, with the standardized mortality
ratio (SMR; shown in parentheses) for the
ranges 0–50, 50–100, 100–200, 200–300,
and 300–400 are 26 (10.0), 12 (4.2), 12
(10.5), 8 (7.7), and 6 (7.5), respectively, for
bladder cancer, and 30 (1.6), 31 (1.4), 21
(2.4), 24 (3.1), and 12 (2.0), respectively,
for lung cancer. Bladder cancer is uniformly
elevated relative to the control population,
but neither the raw case numbers nor the
associated mortality ratios show a positive
trend in the 0–400 µg/L range. The authors
(3) admit that the “computed SMRs display
a large amount of noise.” A better interpre-
tation for the data would be that there is an
unexplained increase in bladder cancer.
Above 600 µg/L, both bladder and lung
cancer are positively correlated with arsenic,
but may be confounded by smoking. 
Regarding the threshold, Morales et al.
(3) used two models to estimate the effective
level of 1/100 risk (ED01); values for male
bladder cancer were 395 and 351 µg/L. The
ED01 is roughly identical with the limit and
the threshold of real risk. Both estimates are
supported by the data and are in line with the
Royal Commission safe level near 250 µg/L
(1) and my interpretation that the threshold
for bladder and lung cancer is > 400 µg/L. 
Scientists have a special obligation if
their interpretations are used by govern-
ments for regulation. That obligation
requires clarification of the statement by
Morales et al. (3) that “… the current stan-
dard of 50 µg/L is associated with a substan-
tial increased risk of cancer” (p. 655). That
statement is not supported by the data. It
should also be kept in mind that two previ-
ous advisory panels on arsenic recommend-
ed that risk should not be extrapolated for
arsenic (5). The most recent of these reports
states that “[the U.S.] EPA has not request-
ed, nor has the subcommittee endeavored to
provide, a formal risk assessment for arsenic
in drinking water” (6; p. 253).
The U.S. EPA has formally adopted the
10 µg/L arsenic standard since this letter was
submitted (7).
Gerhard Stöhrer
Risk Policy Center
Larchmont, New York
E-mail: Gerhardstohrer@aol.com
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